Table 3.
Multivariate analysis of risk factors on outcome parameters.
| RI | NRM | LFS | OS | GRFS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| FluTBI8 (ref.) | 1 | 1 | 1 | 1 | 1 | |||||
| FluBu6.4 | 1.85 (1.16–2.95) | 0.01 | 1.31 (0.72–2.36) | 0.38 | 1.56 (1.09–2.23) | 0.014 | 1.31 (0.84–2.04) | 0.23 | 1.25 (0.92–1.72) | 0.15 |
| FluBu9.6 | 1.51 (0.82–2.77) | 0.19 | 1.91 (0.89–4.1) | 0.099 | 1.63 (1.02–2.58) | 0.039 | 1.41 (0.79–2.54) | 0.25 | 1.1 (0.72–1.7) | 0.65 |
| Age (per 10 y) | 1.25 (0.9–1.74) | 0.19 | 2.1 (1.36–3.24) | 0.0008 | 1.53 (1.18–1.99) | 0.002 | 1.82 (1.33–2.5) | 0.0002 | 1.29 (1.03–1.61) | 0.026 |
| Ph neg B-ALL (ref.) | 1 | 1 | 1 | 1 | 1 | |||||
| Ph pos B-ALL | 0.4 (0.26–0.62) | <0.0001 | 1.21 (0.64–2.27) | 0.56 | 0.59 (0.42–0.83) | 0.003 | 0.61 (0.4–0.93) | 0.021 | 0.68 (0.5–0.91) | 0.011 |
| T-ALL | 0.81 (0.47–1.42) | 0.47 | 2.01 (0.89–4.53) | 0.092 | 1.06 (0.67–1.66) | 0.81 | 1.11 (0.66–1.89) | 0.69 | 1.02 (0.68–1.54) | 0.92 |
| MRD− (ref.) | 1 | 1 | 1 | 1 | 1 | |||||
| MRD+ | 2.02 (1.31–3.11) | 0.001 | 1.01 (0.57–1.8) | 0.97 | 1.53 (1.09–2.14) | 0.014 | 1.34 (0.88–2.04) | 0.17 | 1.45 (1.07–1.95) | 0.015 |
| MRD unknown | 1.1 (0.69–1.76) | 0.68 | 1.04 (0.55–1.97) | 0.9 | 1.06 (0.73–1.52) | 0.77 | 1.25 (0.8–1.93) | 0.33 | 1.09 (0.78–1.51) | 0.62 |
| Year of HCT | 0.98 (0.93–1.04) | 0.59 | 0.97 (0.9–1.04) | 0.36 | 0.98 (0.94–1.02) | 0.27 | 0.97 (0.92–1.03) | 0.31 | 0.99 (0.95–1.03) | 0.55 |
| Female to Male | 0.86 (0.54–1.38) | 0.54 | 1.14 (0.6–2.17) | 0.68 | 0.96 (0.66–1.39) | 0.83 | 0.99 (0.63–1.54) | 0.95 | 0.98 (0.7–1.36) | 0.9 |
| KPS > = 90 | 1.27 (0.86–1.87) | 0.23 | 1.01 (0.6–1.69) | 0.98 | 1.18 (0.87–1.6) | 0.29 | 1.01 (0.7–1.46) | 0.94 | 1.15 (0.88–1.51) | 0.31 |
| MSD (ref.) | 1 | 1 | 1 | 1 | 1 | |||||
| UD 10/10 | 0.67 (0.44–1.01) | 0.059 | 1.34 (0.76–2.36) | 0.31 | 0.86 (0.62–1.2) | 0.37 | 0.82 (0.55–1.23) | 0.34 | 0.94 (0.7–1.26) | 0.67 |
| UD 9/10 | 0.56 (0.29–1.08) | 0.084 | 1.31 (0.61–2.82) | 0.49 | 0.77 (0.48–1.26) | 0.3 | 0.87 (0.49–1.53) | 0.62 | 0.87 (0.57–1.33) | 0.53 |
| PB vs BM | 0.88 (0.44–1.76) | 0.71 | 0.97 (0.37–2.54) | 0.95 | 0.91 (0.52–1.59) | 0.74 | 0.69 (0.36–1.31) | 0.26 | 0.93 (0.57–1.52) | 0.77 |
| in vivo TCD | 0.85 (0.52–1.39) | 0.52 | 0.61 (0.33–1.14) | 0.12 | 0.74 (0.51–1.08) | 0.12 | 0.84 (0.52–1.35) | 0.48 | 0.73 (0.53–1.01) | 0.06 |
| Patient/Donor CMV−/− vs other | 1.21 (0.82–1.81) | 0.34 | 1.17 (0.68–2.03) | 0.57 | 1.21 (0.88–1.67) | 0.23 | 1.16 (0.78–1.7) | 0.46 | 1.27 (0.96–1.67) | 0.092 |
| Centre (frailty) | 0.92 | 0.19 | 0.91 | 0.25 | 0.29 | |||||
HR hazard ratio, CI confidence interval, ref. reference, y year, Ph Philadelphia chromosome, MRD measurable residual disease, HCT hematopoietic cell transplantation, KPS Karnofsky performance status, MSD matched sibling donor, UD unrelated donor, PB peripheral blood, BM bone marrow, TCD T-cell depletion, CMV cytomegalovirus, RI relapse incidence, NRM non-relapse mortality, LFS leukemia-free survival, OS overall survival, GRFS graft-versus-host disease-free/relapse-free survival